Prolongation of Off-Cycle Interval by Finasteride Is Not Associated with Survival Improvement in Intermittent Androgen Deprivation Therapy in LNCaP Tumor Model
September 2009
in “
The Prostate
”
TLDR Finasteride doesn't improve survival in LNCaP tumor model during off-cycle of therapy.
This study investigated whether prolonging the off-cycle interval by finasteride is associated with survival improvement in intermittent androgen deprivation therapy (IADT) in LNCaP tumor model. The results showed that prolonging the off-cycle interval by finasteride did not improve survival in IADT in LNCaP tumor model. The study concluded that maximum possible lengthening of the off-cycle by 5α-reductase inhibition is not associated with survival improvement in this animal model.
